Sale of Western medicine assets--violet ancient Han

"Nanyue Pharmaceutical is sold to China Resources or Hansen, it is still difficult to say." "January 11, Hunan pharmaceutical industry insiders told reporters that China Resources Medicine Group (hereinafter referred to as China Resources Medicine) is interested in the acquisition of Violet Guhanshan (000590). SZ) shares the company Hunan only blood products enterprise Nanyue Pharmaceutical, but previously confirmed to have entered the negotiation stage of the buyers are Hansen pharmaceutical (002412.　　SZ) major shareholder Hanson investment.　　Coincidentally, in addition to stripping biopharmaceutical assets, Violet Guhanshan December 30, 2010 also disclosed that the Hengyang Pharmaceutical Co., Ltd. (hereinafter referred to as Hengyang pharmaceutical) control transfer to Shandong Lu-Chen Xin Pharmaceutical Co., Ltd. (hereinafter referred to as Chen Xin Pharmaceutical industry).　　Stripped of Western medicine assets at the same time, Violet Guhanshan also intends to invest 124 million yuan to expand production of 400 million ancient Han health sperm production capacity, to increase the "Millennium Health side" brand to build, at the same time to recruit prior to the marketing of Hunan Tsinghua Purple Ancient Han Pharmaceutical Co., Ltd. (hereinafter referred to as Guhanshan pharmaceutical) general manager, Violet Ancient Chinese supervisory board chairman Cheng Changheng for the listed company president.　　Violet Guhanshan performance has been hovering in recent years, more than 2009 years caught up Nanyue pharmaceutical stock disputes, the business "one retreat," after the company "stripping Western medicine, strengthen the traditional Chinese medicine," the diversification of the path of contraction increasingly clear. "Blindly diversified, marketing rights Shang, joint venture company profit loss, this is the Violet Guhanshan previous performance lost three major sticking points, the company has in the last year to recover the power of marketing, as for the diversification of the strategy can be effective, it depends on the specific results of the asset stripping, as well as Chinese medicine assets can　　"Changjiang Securities researcher Ye Songtao analysis." Shrink Front Violet Group in 2000, since the arrival of the ancient Han group, has not been listed companies to carry out substantial asset restructuring.　　Days congenial analysis report shows that in recent years, more than 60% of the income of the ancient Chinese and more than 80% of the gross profit from proprietary Chinese medicine, and almost all of the Chinese medicine revenue from Guhanshan Health essence.　　Here, Violet Guhanshan once diversified, in addition to dabbling in Western medicine and bio-pharmaceuticals, but also invested in Shenzhen Longjiang Pig wholesale market, Guhan Jiang Chinese turtle Aquaculture Company, Jilin Ji ' an deer farm and other 9 companies, but all to the loss. Blind diversification of the company's performance for many years to linger.　　2001 2009, Purple Ancient Han main income has been hovering around 200 million yuan, 2006 years ago the company's long-term meager profit, has always struggled in the profit and Loss Edge, 2009, the company's larger loss of 88.16 million yuan, 9 years, the company's earnings per share has never exceeded 0.1 yuan, and never to shareholders dividends. Compounding that, in 2006, with Nanyue Pharma controlling the right to Shang, the Guhanshan's bio-pharmaceutical premium assets were lost, and almost every year the profits of Nanyue Pharmaceuticals were made into the pockets of the Avatar creature.　　Beginning in 2009, the management of the big Blood exchange of violet Guhanshan ready to take back Nanyue pharmaceutical control, with Nanyue Pharmaceutical equity disputes in the open, the scene of biological, Gottia, Hansen Investment has been involved in, recently more news that China Resources Medicine is also interested in mergers and acquisitions Nanyue pharmaceutical. Hansen's investment in the company has a new and medium-sized SME listed companies in the pharmaceutical, capital chargeYu, while China Resources medicine relies on the abundant resources of China Resources group, the ability to integrate assets more powerful, prior to its capital operation will be 39 (000999.　　SZ) and Donga donkey-hide-gelatin (000423.SZ) two listed pharmaceutical companies integrated into their own. "Big shareholder Purple Light Group wants to sell Hansen, two shareholder Hengyang Sasac more likes China resources."　　"According to the industry, the two major shareholders of the purple-violet ancient and Chinese companies have basically reached a consensus on the sale of Nanyue pharmaceutical shares, but ultimately Nanyue pharmaceutical companies Hanson Investment or the central enterprise of China Resources Medicine, is unknown." Nanyue Pharmaceutical equity dispute has not been final, Violet Guhanshan is ready to be stripped of its western medicine assets.　　December 28, 2010, the company and Chen Xin Pharmaceutical and Tongde Xiang Medicine signed a cooperation framework agreement, the 2009 loss of 45.14 million yuan of Hengyang pharmaceutical holding power to let and Chen Xin Pharmaceutical, he became the main infusion and other Western medicine business Company's equity shareholders. Diversification shrinks or brings a lot of short-term profits to Violet Guhanshan.　　In 2009, the company made a profit in the three quarter from 2010 years ago by significantly reducing the value of its assets.　　And the reporter learned that the transfer of Nanyue pharmaceutical shares at least for the purple Guhanshan bring 60 million yuan income, plus the transfer of Hengyang Pharmaceutical holding right to the price, Violet Guhanshan 2011 years to maintain profitability should be no problem.　　Get rid of the burden of the western medicine business, Violet Guhanshan in ancient Chinese medicine for the core of traditional Chinese herbal health products in the field began exerting force. December 27, 2010, the company's interim shareholders meeting through the ancient Han health-intensive production capacity expansion motion: Purple Ancient Han wholly-owned subsidiary of Hengyang Chinese Medicine Company will invest 124 million yuan to build "annual output of 400 million ancient Chinese oral health care Refining Project."　　Project up to the postpartum, is expected to increase the operating income of 625 million yuan per year, net profit of 106 million yuan. "Purple Ancient Han before the management of the existence of a lot of unreasonable places, you can say is not allowed to let, should not take the take, health-intensive expansion can be said to be a rectification."　　Ye Songtao bluntly.　　He said that the Nanyue pharmaceutical holding power, the ancient Han Dynasty health wine holding power and the ancient Han health fine marketing right had not been in the purple and ancient Han's grasp for a long time, this can be said that is not allowed to let, "and infusion business has never been the company's strengths, the company has been caught in the hands, you can say that take the".　　Violet Guhanshan Vice President Nanyan had told reporters that after a long time, the purple and ancient Han joint venture marketing company's holding power in the hands of the joint venture, leading to the ancient Han health fine sales rights are the other side, while the ancient Han health wine joint venture company, the proportion of the ancient Han Chinese shares less than 20%. But now Violet Guhanshan has begun to clean up the mess.　　2010, the company withdrew the joint-venture marketing company's controlling power, and the establishment of Changsha marketing company and Hengyang Marketing company, Guhanshan Health fine sales right finally returned to the hands of the listed companies, and the reporter learned that the company is still in the beginning to recover the ancient Chinese health wine holding power. "The key to the company's rectification lies in the expansion of ancient Chinese health and the sale of the province outside."　"Ye Songtao analysis.　The company insiders revealed that the newly launched the 400 million ancient Han health refined production capacity, the main consideration is the future of the market demand outside the province. And Cheng Changheng, chairman of the Board of Supervisors, was hired as the company's president, was unanimously regarded as a company to strengthen marketing arrangements.　　Reporter learned that Cheng Changheng previously served as the general manager of ancient Chinese medicine, counterpart director of the ancient Han Changsha marketing company and Hengyang Marketing company business. "The transformation curtain has been opened, just Violet Guhanshan after nine years toss, its success in the province of marketing experience grafting to the province outside the market, Violet Group and Hengyang state-funded committee will continue to take control of the listed companies, this will be considered the wisdom of the company's senior management problems." "The people in the industry expressed their concern about the development of the purple-violet ancient Han."